A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

February 12, 2024

Study Completion Date

February 12, 2024

Conditions
Schizophrenia
Interventions
DRUG

SEP-363856

SEP-363856 will be supplied as over-encapsulated tablets. Multiple tablets may be required to achieve a single dose.

DRUG

Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)

PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.

Trial Locations (4)

45417

Midwest Clinical Research Center, Dayton

72211

Woodland International Research Group, Little Rock

72758

Shari DeSilva, Rogers

78240

Endeavor Clinical Trials, San Antonio

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY